Morgan Stanley Says Elevance Health's Growth Attributed To Consistent Performance But Undervalued
Benzinga • 602 days
Low Materiality0/10
Information
Morgan Stanley has initiated coverage on Elevance Health Inc ELV, an American health insurance provi...
Original sourceAI Summary
- Morgan Stanley initiates coverage on Elevance Health Inc citing compelling risk-reward. - Balanced presence in Medicare Advantage, Commercial, and Medicaid segments helps withstand challenges. - Undervalued potential in Pharmacy Benefit Management, Specialty Pharmacy, and Carelon Services. - Overweight rating with price target of $643, undervaluation unjustified given diversified portfolio. Price Impact Rating: bullish Impact Horizon Rating: long-term Type: Analyst Rating
Market-Moving
- Morgan Stanley initiates coverage on Elevance Health Inc citing compelling risk-reward.
- Balanced presence in Medicare Advantage, Commercial, and Medicaid segments helps withstand challenges.
- Undervalued potential in Pharmacy Benefit Management, Specialty Pharmacy, and Carelon Services.
Key Facts
- Morgan Stanley initiates coverage on Elevance Health Inc citing compelling risk-reward.
- Balanced presence in Medicare Advantage, Commercial, and Medicaid segments helps withstand challenges.
- Undervalued potential in Pharmacy Benefit Management, Specialty Pharmacy, and Carelon Services.
- Overweight rating with price target of $643, undervaluation unjustified given diversified portfolio.